Clarke, Amanda

Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial.

McCormack, S., Dunn, D. T., Desai, M., Dolling, D. I., Gafos, M., Gilson, R., Sullivan, A. K., Clarke, A., Reeves, I., Schembri, G., et al. (2016) · The Lancet

HIV/AIDS Research and InterventionsHIV/AIDS drug development and treatment

Cited by 1,878

Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER) primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial

Mayer, K. H., Molina, J.-M., Thompson, M. A., Anderson, P. L., Mounzer, K. C., De Wet, J. J., DeJesus, E., Jessen, H., Grant, R. M., Ruane, P. J., et al. (2020) · The Lancet

HIV/AIDS Research and InterventionsHIV/AIDS drug development and treatment

Cited by 428

An analysis of baseline data from the PROUD study: an open-label randomised trial of pre-exposure prophylaxis.

On behalf of the PROUD Study Group, Dolling, D. I., Desai, M., McOwan, A., Gilson, R., Clarke, A., Fisher, M., Schembri, G., Sullivan, A. K., Mackie, N., et al. (2016) · Trials

HIV/AIDS Research and InterventionsHIV, Drug Use, Sexual Risk

Cited by 51